Emerging Technologies for the Detection of Cancer Micrometastasis

Mao, Xuqing; Mei, Ruyi; Yu, Shu-Xian; Shou, Lan; Zhang, Wenzheng; Li, Keshuai; Qiu, Zejing; Xie, Tian; Sui, Xinbing

doi:10.1177/15330338221100355

Cited by 12 publications

(5 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…When locoregional microscopical residual disease was present, our scans would have missed the diagnosis of residual disease, but microscopical locoregional residual disease will eventually translate to locoregional recurrence. MRI, and 18F[FDG]-PET/CT cannot detect micro metastases, but these metastases may have a significant impact on prognosis and might affect treatment plans [ 15 ]. Also, we included patients from 2005 to 2018 to obtain longer follow-up periods, and in the last years, the availability and quality of radiological imaging improved, which may have led to a higher accuracy [ 16 ].…”

Section: Discussionmentioning

confidence: 99%

Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer

van Kol,

Ebisch,

Beugeling

et al. 2023

Cancers

View full text Add to dashboard Cite

Objectives: There is no consensus on the most reliable procedure to determine remission of cervical cancer after chemoradiotherapy (CRT). Therefore, this study aims to assess the diagnostic performance of two different imaging techniques, MRI and 18F[FDG]-PET/CT, in determining the presence of locoregional residual disease after CRT in patients with locally advanced cervical cancer. Methods: Patients diagnosed with locally advanced cervical cancer (FIGO 2009) treated with CRT were retrospectively identified from a regional cohort. The accuracy of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was assessed with histology as the reference standard. Results: The negative predictive value (NPV) and positive predictive value (PPV) for locoregional residual disease detection of MRI and 18F[FDG]-PET/CT combined were 84.2% (95% CI 73.2–92.1), and 70.4% (95% CI 51.8–85.2), respectively. The NPV and PPV of MRI alone were 80.2% (95% CI 71.2–87.5) and 47.7% (95% CI 35.8–59.7), respectively, and values of 81.1% (95% CI 72.2–88.3) and 55.8 (95% CI 42.2–68.7), respectively, were obtained for 18F[FDG]-PET/CT alone. Conclusion: In this study, the reliability of MRI and 18F[FDG]-PET/CT in detecting locoregional residual disease was limited. Combining MRI and 18F[FDG]-PET/CT did not improve predictive values. Routine use of both MRI and 18F[FDG]-PET/CT in the follow-up after CRT should be avoided. MRI during follow-up is the advised imaging technique. Pathology confirmation of the presence of locoregional residual disease before performing salvage surgery is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer

van Kol,

Ebisch,

Beugeling

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…CTSD has been implicated in tumor invasion and metastasis in different tumor models and has also been proposed as a possible biomarker of OS [30,31]. CTSD, which is increased in metastatic cells, has also been reported to have a role in protecting against apoptosis [14].…”

Section: Discussionmentioning

confidence: 99%

“…Since the 1970s, patients with metastatic disease have not presented signi cant changes in the 5-year survival rate of 15-30%. The appearance of micrometastases represents a major complication since they are not detectable by conventional methods [14].…”

Section: Introductionmentioning

confidence: 99%

Osteosarcoma cells relate functionally with stromal cells favoring a lung niche permissive for the establishment of metastatic tumor cells

Alvarez,

Gutierrez,

Bayo

et al. 2023

Preprint

View full text Add to dashboard Cite

Osteosarcoma (OS) is the most common bone tumor and 20% of the patients are diagnosed with metastatic OS at first diagnosis. Undetectable metastases at the time of diagnosis are also a major complication. MSCs display abilities that enable tumor growth. We demonstrated that in vitro, MSCs migrated more towards the secretome of non-metastatic OS cells. When challenged to a secretome from lungs pre-loaded with OS cells, MSCs migrated more towards lungs colonized with metastatic OS cells. Furthermore, MSCs had a preferential migratory and homing behavior in vivo towards lungs´ colonized by metastatic OS cells. In addition, metastatic OS cells showed a higher migratory response towards the MSCs secretome. This feature partnered with increased CTSD expression and release of active MMP2 by metastatic OS cells. We assessed two complementary tumor capabilities relevant to metastatic spread, highlighting the importance of inherent cell features, but also underlining the importance of signaling integration across the niche, suggesting that an interplay of migratory responses between already established OS cells in the lungs, prometastatic OS cells in the primary tumor, and circulating MSCs. Pulmonary metastases remain as a major determinant of OS mortality, and identification of mechanisms and differentially expressed genes would help identify markers and targets for therapeutic approaches of metastatic spread.

show abstract

“…It is unquestionable that CTCs have significant advantages as potential biomarkers for RCC. In addition to being obtained non-invasively, they reflect tumor heterogeneity, are exceedingly specific for RCC and allow for cell analysis at structural (based on physical properties and surface markers), molecular (through nucleic acids and proteins) and genomic (through sequencing) levels [105,106]. These features entail the use of CTCs in clinical practice, mostly in prognosis, prediction of response to treatment and disease monitoring.…”

Section: Future Directionsmentioning

confidence: 99%

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?

Couto-Cunha

Jerónimo

Henrique

2022

Cancers

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is among the 15 most common cancers worldwide, with rising incidence. In most cases, this is a silent disease until it reaches advance stages, demanding new effective biomarkers in all domains, from detection to post-therapy monitoring. Circulating tumor cells (CTC) have the potential to provide minimally invasive information to guide assessment of the disease’s aggressiveness and therapeutic strategy, representing a special pool of neoplastic cells which bear metastatic potential. In some tumor models, CTCs’ enumeration has been associated with prognosis, but there is a largely unexplored potential for clinical applicability encompassing screening, diagnosis, early detection of metastases, prognosis, response to therapy and monitoring. Nonetheless, lack of standardization and high cost hinder the translation into clinical practice. Thus, new methods for collection and analysis (genomic, proteomic, transcriptomic, epigenomic and metabolomic) are needed to ascertain the role of CTC as a RCC biomarker. Herein, we provide a critical overview of the most recently published data on the role and clinical potential of CTCs in RCC, addressing their biology and the molecular characterization of this remarkable set of tumor cells. Furthermore, we highlight the existing and emerging techniques for CTC enrichment and detection, exploring clinical applications in RCC. Notwithstanding the notable progress in recent years, the use of CTCs in a routine clinical scenario of RCC patients requires further research and technological development, enabling multimodal analysis to take advantage of the wealth of information they provide.

show abstract

Emerging Technologies for the Detection of Cancer Micrometastasis

Cited by 12 publications

References 100 publications

Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer

Comparing Methods to Determine Complete Response to Chemoradiation in Patients with Locally Advanced Cervical Cancer

Osteosarcoma cells relate functionally with stromal cells favoring a lung niche permissive for the establishment of metastatic tumor cells

Circulating Tumor Cells as Biomarkers for Renal Cell Carcinoma: Ready for Prime Time?

Contact Info

Product

Resources

About